Clinical Trials Browser

Phase 1/2 × Neurofibrosarcoma × 1 year × Clear all

NCT05642455 2026-02-09

SPEARHEAD-3 Pediatric Study

Phase 1/2 Recruiting

Neuroblastoma, Osteosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT06239272 2026-01-26

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Phase 1/2 Enrolling by invitation

BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

NCT05275478 2025-11-14

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Active not recruiting

CNSGastrointestinalOther solid neoplasmSarcomaThoracic

Glioblastoma, Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT05732831 2025-11-14

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Recruiting

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT06735820 2025-07-03

MEKMDM2

Phase 1/2 Not yet recruiting

Neurofibromatosis 1, Neurofibrosarcoma

NCT02584647 2025-03-21

PLX3397

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma